Skip to main content
SpringerLink
Log in

Pharmacological Strategies for Enhancing Cognition in Schizophrenia

  • Chapter
  • First Online:
Behavioral Neurobiology of Schizophrenia and Its Treatment

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 4))

Abstract

Researchers have long recognized that individuals with schizophrenia experience challenges in a wide range of cognitive domains, and research on cognitive impairment in schizophrenia is not a recent phenomena. However, the past 10–20 years have seen an increasing recognition of the central importance of cognition to understanding function and outcome in this illness (Green et al. in Schizophr Bull 26:119–136, 2000), an awareness that has shifted the emphasis of at least some work on schizophrenia. More specifically, there has been a rapidly growing body of work on methods of enhancing cognition in schizophrenia, as a means to potentially facilitate improved outcome and quality of life for individuals with this debilitating illness. The current chapter reviews the results of a range of studies examining adjunctive pharmacological treatments to enhance cognition in schizophrenia using a range of designs, including single-dose studies, open-label repeated dosing studies, and double-blind parallel group and crossover designs with repeated dosing. Although many of the single-dose and open-label studies have suggested positive cognitive effects from a range of agents, few of the larger-scale double-blind studies have generated positive results. The current state of results may reflect the need to identify alternative molecular mechanisms for enhancing cognition in schizophrenia or the need to reconceptualize the ways in which pharmacological agents may improve cognition in this illness, with a concomitant change in the traditional clinical trial study design used in prior studies of cognitive enhancement in schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aasen I, Kumari V, Sharma T (2005) Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study. J Clin Psychopharmacol 25:311–317

    Article  PubMed  CAS  Google Scholar 

  • Adams CE, Stevens KE (2007) Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Front Biosci 12:4755–4772

    Article  PubMed  CAS  Google Scholar 

  • Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189–202

    Article  PubMed  CAS  Google Scholar 

  • AhnAllen CG, Nestor PG, Shenton ME, McCarley RW, Niznikiewicz MA (2008) Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia. Schizophr Res 100:261–269

    Article  PubMed  Google Scholar 

  • Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, Rezazadeh SA (2008) A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1810–1815

    Article  PubMed  CAS  Google Scholar 

  • Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch Gen Psychiatry 57:270–276

    Article  PubMed  CAS  Google Scholar 

  • Arendt T, Schugens MM, Bigl V (1990) The cholinergic system and memory: amelioration of ethanol-induced memory deficiency by physostigmine in rat. Acta Neurobiol Exp (Wars) 50:251–261

    CAS  Google Scholar 

  • Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116:143–151

    Article  PubMed  CAS  Google Scholar 

  • Barch DM (2005) The cognitive neuroscience of schizophrenia. In: Cannon T, Mineka S (eds) Annual review of clinical psychology, vol 1. American Psychological Association, Washington, DC, pp 321–353

    Google Scholar 

  • Barch DM, Carter CS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 77:43–58

    Article  PubMed  Google Scholar 

  • Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Deckersbach T, Kelly JF, Freudenreich O, Goff DC, Evins AE (2008) The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33:480–490

    Article  PubMed  CAS  Google Scholar 

  • Barr MS, Farzan F, Rusjan PM, Chen R, Fitzgerald PB, Daskalakis ZJ (2009) Potentiation of gamma oscillatory activity through repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex. Neuropsychopharmacology 34:2359–2367

    Article  PubMed  Google Scholar 

  • Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D’Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S (2009) Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 24:233–238

    Article  PubMed  CAS  Google Scholar 

  • Berman JA, Talmage DA, Role LW (2007) Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol 78:193–223

    Article  PubMed  CAS  Google Scholar 

  • Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE (2009) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev CD001191

    Google Scholar 

  • Bleuler E (1950) Dementia praecox, or the group of schizophrenias. International Universities Press, New York, NY

    Google Scholar 

  • Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S (2000) Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23:351–364

    Article  PubMed  CAS  Google Scholar 

  • Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979) Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205:929–931

    Article  PubMed  CAS  Google Scholar 

  • Buchanan RW, Summerfelt A, Tek C, Gold J (2003) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59:29–33

    Article  PubMed  Google Scholar 

  • Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA (2007a) Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 33:1120–1130

    Article  PubMed  Google Scholar 

  • Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT (2007b) The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164:1593–1602

    Article  PubMed  Google Scholar 

  • Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165:82–89

    Article  PubMed  Google Scholar 

  • Buchanan RW, Marder S, Group TT (2010) MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Schizophr Res

    Google Scholar 

  • Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711

    Article  PubMed  CAS  Google Scholar 

  • Cai JX, Arnsten AFT (1997) Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther 283:183–189

    PubMed  CAS  Google Scholar 

  • Camon L, de Vera N, Martinez E (2001) Polyamine metabolism and glutamate receptor agonists-mediated excitotoxicity in the rat brain. J Neurosci Res 66:1101–1111

    Article  PubMed  CAS  Google Scholar 

  • Carter CS, Barch DM (2007) Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull 33:1131–1137

    Article  PubMed  Google Scholar 

  • Castner SA, Williams GV, Goldman-Rakic PS (2000) Reversal of antipsychotic induced working memory deficits by short term dopamine D1 receptor stimulation. Science 287:2020–2022

    Article  PubMed  CAS  Google Scholar 

  • Cervellione KL, Burdick KE, Cottone JG, Rhinewine JP, Kumra S (2007) Neurocognitive deficits in adolescents with schizophrenia: longitudinal stability and predictive utility for short-term functional outcome. J Am Acad Child Adolesc Psychiatry 46:867–878

    Article  PubMed  Google Scholar 

  • Cho RY, Konecky RO, Carter CS (2006) Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci USA 103:19878–19883

    Article  PubMed  CAS  Google Scholar 

  • Chouinard S, Stip E, Poulin J, Melun JP, Godbout R, Guillem F, Cohen H (2007) Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin 23:575–583

    Article  PubMed  CAS  Google Scholar 

  • Chung YC, Lee CR, Park TW, Yang KH, Kim KW (2009) Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J Biol Psychiatry 10:156–162

    Article  PubMed  Google Scholar 

  • Cincotta SL, Yorek MS, Moschak TM, Lewis SR, Rodefer JS (2008) Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr Opin Investig Drugs 9:47–56

    PubMed  CAS  Google Scholar 

  • Clark CR, Geffen GM, Geffen LB (1986) Role of monoamine pathways in the control of attention: effects of droperidol and methylphenidate on normal adult humans. Psychopharmacology 90:28–34

    PubMed  CAS  Google Scholar 

  • Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM (2002) Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 125:584–594

    Article  PubMed  Google Scholar 

  • Cooper JA, Sagar JH, Doherty SM, Jordan N, Tidswell P, Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease: a follow-up study of untreated patients. Brain 115:1701–1725

    Article  PubMed  Google Scholar 

  • Cornblatt B, Obuchowski M, Roberts S, Pollack S, Erlenmeyer-Kimling L (1999) Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 11:487–508

    Article  PubMed  CAS  Google Scholar 

  • Costa A, Peppe A, Dell'Agnello G, Carlesimo GA, Murri L, Bonuccelli U, Caltagirone C (2003) Dopaminergic modulation of visual–spatial working memory in Parkinson's disease. Dement Geriatr Cogn Disord 15:55–66

    Article  PubMed  CAS  Google Scholar 

  • Crook JM, Dean B, Pavey G, Copolov D (1999) The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 64:1761–1771

    Article  PubMed  CAS  Google Scholar 

  • Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48:381–388

    Article  PubMed  CAS  Google Scholar 

  • Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001) Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158:918–925

    PubMed  CAS  Google Scholar 

  • Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, Griffith J, Adler LE, Freedman R (1993) Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res 10:131–141

    Article  PubMed  CAS  Google Scholar 

  • Dajas-Bailador FA, Heimala K, Wonnacott S (2003) The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol 64:1217–1226

    Article  PubMed  CAS  Google Scholar 

  • Daniel DG, Weinberger DR, Jones DW, Smernoff E, Madison A, Nagamoto HT, Griffith J, Adler LE, Freedman R (1991) The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11:1907–1917

    PubMed  CAS  Google Scholar 

  • Delawalla Z, Barch DM, Fisher Eastep JL, Thomason ES, Hanewinkel MJ, Thompson PA, Csernansky JG (2006) Factors mediating cognitive deficits and psychopathology among siblings of individuals with schizophrenia. Schizophr Bull 32:525–537

    Article  PubMed  Google Scholar 

  • Delle Chiaie R, Salviati M, Fiorentini S, Biondi M (2007) Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol 15:563–568

    Article  PubMed  CAS  Google Scholar 

  • Deng C, Huang XF (2005) Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia. J Neurosci Res 81:883–890

    Article  PubMed  CAS  Google Scholar 

  • Depatie L, O'Driscoll GA, Holahan AL, Atkinson V, Thavundayil JX, Kin NN, Lal S (2002) Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 27:1056–1070

    Article  PubMed  CAS  Google Scholar 

  • Didato G, Nobili L (2009) Treatment of narcolepsy. Expert Rev Neurother 9:897–910

    Article  PubMed  CAS  Google Scholar 

  • Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE (2008) High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 102:88–95

    Article  PubMed  Google Scholar 

  • Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917–6922

    Article  PubMed  CAS  Google Scholar 

  • Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131:196–206

    Article  PubMed  CAS  Google Scholar 

  • Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA (2005) Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 28:179–184

    Article  PubMed  CAS  Google Scholar 

  • Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (2008) The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154:1166–1181

    Article  PubMed  CAS  Google Scholar 

  • Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826–828

    Article  PubMed  CAS  Google Scholar 

  • Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002) d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56:19–23

    Article  PubMed  Google Scholar 

  • Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY (2007) Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol 30:3–12

    Article  PubMed  CAS  Google Scholar 

  • Farzan F, Barr MS, Wong W, Chen R, Fitzgerald PB, Daskalakis ZJ (2009) Suppression of gamma-oscillations in the dorsolateral prefrontal cortex following long interval cortical inhibition: a TMS-EEG study. Neuropsychopharmacology 34:1543–1551

    Article  PubMed  CAS  Google Scholar 

  • Fayen M, Goldman MB, Moulthrop MA, Luchins DJ (1988) Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. Am J Psychiatry 145:483–486

    PubMed  CAS  Google Scholar 

  • Floresco SB, Geyer MA, Gold LH, Grace AA (2005) Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull 31:888–894

    Article  PubMed  Google Scholar 

  • Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38:22–33

    Article  PubMed  CAS  Google Scholar 

  • Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040–1047

    Article  PubMed  Google Scholar 

  • Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, Goff DC (2005) Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 181:358–363

    Article  CAS  Google Scholar 

  • Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, Walsh JP, Goff DC (2009) Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry 70(12):1674–1680

    Article  PubMed  CAS  Google Scholar 

  • Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349–357

    Article  PubMed  CAS  Google Scholar 

  • Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L, Parrella M, Bowler S, Elbaz Z, Flanagan L, Harvey PD (2008) A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 28:59–63

    Article  PubMed  CAS  Google Scholar 

  • Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH (2005) Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol Psychiatry 57:155–161

    Article  PubMed  CAS  Google Scholar 

  • George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB (2007) A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 93:42–50

    Article  PubMed  Google Scholar 

  • Geyer MA (2008) Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res 14:71–78

    Article  PubMed  CAS  Google Scholar 

  • Glahn DC, Therman S, Manninen M, Huttunen M, Kaprio J, Lönnqvist J, Cannon TD (2003) Spatial working memory as an endophenotype for schizophrenia. Biol Psychiatry 53:624–626

    Article  PubMed  Google Scholar 

  • Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213–1215

    PubMed  CAS  Google Scholar 

  • Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996) d-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628–1630

    PubMed  CAS  Google Scholar 

  • Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999) A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21–27

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G (2001) A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21:484–487

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D (2005) A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 179:144–150

    Article  CAS  Google Scholar 

  • Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL (2007) Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 27:582–589

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF (2008a) Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 106:320–327

    Article  PubMed  Google Scholar 

  • Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA (2008b) A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 33:465–472

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, Walsh JP (2009) A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl) 202:411–417

    Article  CAS  Google Scholar 

  • Gold PE (2003) Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 80:194–210

    Article  PubMed  CAS  Google Scholar 

  • Gold PE (2004) Coordination of multiple memory systems. Neurobiol Learn Mem 82:230–242

    Article  PubMed  Google Scholar 

  • Gold JM, Goldberg RW, McNary SW, Dixon LB, Lehman AF (2002) Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 159:1395–1402

    Article  PubMed  Google Scholar 

  • Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE (1991) Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 148:78–84

    PubMed  CAS  Google Scholar 

  • Goldman-Rakic PS, Muly EC, Williams GV (2000) D1 receptors in prefrontal cells and circuits. Brain Res Rev 31:295–301

    Article  PubMed  CAS  Google Scholar 

  • Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng C, Wess J (1999) Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96:10483–10488

    Article  PubMed  CAS  Google Scholar 

  • Gomeza J, Zhang L, Kostenis E, Felder CC, Bymaster FP, Brodkin J, Shannon H, Xia B, Duttaroy A, Deng CX, Wess J (2001) Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. Life Sci 68:2457–2466

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez-Burgos G, Kroener S, Seamans JK, Lewis DA, Barrionuevo G (2005) Dopaminergic modulation of short-term synaptic plasticity in fast-spiking interneurons of primate dorsolateral prefrontal cortex. J Neurophysiol 94:4168–4177

    Article  PubMed  CAS  Google Scholar 

  • Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 26:119–136

    Article  PubMed  CAS  Google Scholar 

  • Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R (1998) Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 44:98–106

    Article  PubMed  CAS  Google Scholar 

  • Guillem F, Chouinard S, Poulin J, Godbout R, Lalonde P, Melun P, Bentaleb LA, Stip E (2006) Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial. Prog Neuropsychopharmacol Biol Psychiatry 30:934–945

    Article  PubMed  CAS  Google Scholar 

  • Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B, Zerbe G, Freedman R (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29:1378–1385

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto T, Arion D, Unger T, Maldonado-Avilés JG, Morris HM, Volk DW, Mirnics K, Lewis DA (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13:147–161

    Article  PubMed  CAS  Google Scholar 

  • Hasselmo ME (2006) The role of acetylcholine in learning and memory. Curr Opin Neurobiol 16:710–715

    Article  PubMed  CAS  Google Scholar 

  • Heinrichs RW, Goldberg JO, Miles AA, McDermid Vaz S (2008) Predictors of medication competence in schizophrenia patients. Psychiatry Res 157:47–52

    Article  PubMed  Google Scholar 

  • Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617

    Article  PubMed  CAS  Google Scholar 

  • Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J (1998) Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1:131–135

    Article  PubMed  Google Scholar 

  • Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29–36

    Article  PubMed  CAS  Google Scholar 

  • Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC (2004) High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55:165–171

    Article  PubMed  CAS  Google Scholar 

  • Hong LE, Schroeder M, Ross TJ, Buchholz B, Salmeron BJ, Wonodi I, Thaker GK, Stein EA (2009) Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull [Epub ahead of print, Aug 27]

    Google Scholar 

  • Hunter MD, Ganesan V, Wilkinson ID, Spence SA (2006) Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry 163:2184–2186

    Article  PubMed  Google Scholar 

  • Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH (2004) Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 55:850–858

    Article  PubMed  CAS  Google Scholar 

  • Javitt DC (2008) Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 63:6–8

    Article  PubMed  CAS  Google Scholar 

  • Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308

    PubMed  CAS  Google Scholar 

  • Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE (2008) Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology (Berl) 199:89–98

    Article  CAS  Google Scholar 

  • Kamei C, Tsujimoto S, Tasaka K (1990) Effects of cholinergic drugs and cerebral metabolic activators on memory impairment in old rats. J Pharmacobiodyn 13:772–777

    Article  PubMed  CAS  Google Scholar 

  • Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R (2008) Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33:1217–1228

    Article  PubMed  CAS  Google Scholar 

  • Kem WR, Mahnir VM, Prokai L, Papke RL, Cao X, LeFrancois S, Wildeboer K, Prokai-Tatrai K, Porter-Papke J, Soti F (2004) Hydroxy metabolites of the Alzheimer’s drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol 65:56–67

    Article  PubMed  CAS  Google Scholar 

  • Kimberg DY, D'Esposito M (2003) Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 41:1020–1027

    Article  PubMed  Google Scholar 

  • Kimberg DY, D’Esposito M, Farah MJ (1997) Effects of bromocriptine on human subjects depend on working memory capacity. NeuroReport 8:381–385

    Article  Google Scholar 

  • Kirrane RM, Mitropoulou V, Nunn M, New AS, Harvey PD, Schopick F, Silverman J, Siever LJ (2000) Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder. Neuropsychopharmacology 22:14–18

    Article  PubMed  CAS  Google Scholar 

  • Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC (2007) No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 12:412–421

    Article  PubMed  Google Scholar 

  • Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, Nakazato M, Okamura N, Stevens KE, Freedman R, Iyo M (2005) Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 76:67–72

    Article  PubMed  Google Scholar 

  • Konopaske GT, Sweet RA, Wu Q, Sampson A, Lewis DA (2006) Regional specificity of chandelier neuron axon terminal alterations in schizophrenia. Neuroscience 138:189–196

    Article  PubMed  CAS  Google Scholar 

  • Kraeplin E (1950) Dementia praecox and paraphrenia. International Universities Press, New York, NY

    Google Scholar 

  • Krivoy A, Weizman A, Laor L, Hellinger N, Zemishlany Z, Fischel T (2008) Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. Eur Neuropsychopharmacol 18:117–121

    Article  PubMed  CAS  Google Scholar 

  • Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A (1996) Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 199:2121–2132

    Article  Google Scholar 

  • Kulisevsky J, Garcia-Sanchex C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estévez-González A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two year follow-up study of previously untreated patients. Mov Disord 15:613–626

    Article  PubMed  CAS  Google Scholar 

  • Kumar R (2008) Approved and investigational uses of modafinil: an evidence-based review. Drugs 68:1803–1839

    Article  PubMed  CAS  Google Scholar 

  • Kumari V, Postma P (2005) Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 29:1021–1034

    Article  PubMed  CAS  Google Scholar 

  • Kumari V, Aasen I, ffytche D, Williams SC, Sharma T (2006) Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. NeuroImage 29:545–556

    Article  PubMed  Google Scholar 

  • Lange KW, Paul GM, Naumann M, Gsell W (1995) Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J Neural Transm 46:423–432

    CAS  Google Scholar 

  • Lee BJ, Lee JG, Kim YH (2007a) A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol 21:421–427

    Article  PubMed  CAS  Google Scholar 

  • Lee SW, Lee JG, Lee BJ, Kim YH (2007b) A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 22:63–68

    Article  PubMed  CAS  Google Scholar 

  • Lenzi A, Maltinti E, Poggi E, Fabrizio L, Coli E (2003) Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol 26:317–321

    Article  PubMed  CAS  Google Scholar 

  • Leonard S, Mexal S, Freedman R (2007) Smoking, genetics and schizophrenia: evidence for self medication. J Dual Diagn 3:43–59

    Article  PubMed  Google Scholar 

  • Levin ED, Wilson W, Rose JE, McEvoy J (1996) Nicotine–haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429–436

    Article  PubMed  CAS  Google Scholar 

  • Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71(2):138–149

    Google Scholar 

  • Lewis DA, Hashimoto T (2007) Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int Rev Neurobiol 78:109–131

    Article  PubMed  CAS  Google Scholar 

  • Lewis DA, Moghaddam B (2006) Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 63:1372–1376

    Article  PubMed  Google Scholar 

  • Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312–324

    Article  PubMed  CAS  Google Scholar 

  • Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, Montrose D (2008) Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 165:1585–1593

    Article  PubMed  Google Scholar 

  • Lieberman JA, Javitch JA, Moore H (2008) Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry 165:931–936

    Article  PubMed  Google Scholar 

  • Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A, MEM-MD-29 Study Group (2009) A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34:1322–1329

    Article  PubMed  CAS  Google Scholar 

  • Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234–242

    Article  PubMed  CAS  Google Scholar 

  • Luciana M, Collins PF (1997) Dopamine modulates working memory for spatial but not object cues in normal humans. J Cogn Neurosci 4:58–68

    Article  Google Scholar 

  • Luciana M, Depue RA, Arbisi P, Leon A (1992) Facilitation of working memory in humans by a D2 dopamine receptor agonist. J Cogn Neurosci 4:58–68

    Article  Google Scholar 

  • Luciana M, Collins PF, Depue RA (1998) Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 8:218–226

    Article  PubMed  CAS  Google Scholar 

  • Luntz-Leybman V, Bickford PC, Freedman R (1992) Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 587:130–136

    Article  PubMed  CAS  Google Scholar 

  • Malhotra AK, Kestler LJ, Mazzanti CM, Bates JA, Goldberg TE, Goldman D (2002) A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 159:652–654

    Article  PubMed  Google Scholar 

  • Mandel RJ, Chen AD, Connor DJ, Thal LJ (1989) Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. J Pharmacol Exp Ther 251:612–619

    PubMed  CAS  Google Scholar 

  • Marder SR, Fenton W (2004) Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72:5–9

    Article  PubMed  Google Scholar 

  • Martin LF, Freedman R (2007) Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 78:225–246

    Article  PubMed  CAS  Google Scholar 

  • Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R, Perry E, Nordberg A (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22:115–126

    Article  PubMed  CAS  Google Scholar 

  • Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, Shampine LJ (2009) Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 34:1885–1903

    Article  PubMed  CAS  Google Scholar 

  • Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB, Weinberger DR (1996) Dextroamphetamine enhances “neural network-specific” physiological signals: a positron-emission tomography rCBF study. J Neurosci 15:4816–4822

    Google Scholar 

  • Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, Berman KF, Goldberg TE, Weinberger DR (2000) Effects of dextroamphetamine on cognitive performance and cortical activation. NeuroImage 12:268–275

    Article  PubMed  CAS  Google Scholar 

  • Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR (2003) Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100:6186–6191

    Article  PubMed  CAS  Google Scholar 

  • McClure MM, Bowie CR, Patterson TL, Heaton RK, Weaver C, Anderson H, Harvey PD (2007) Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships? Schizophr Res 89:330–338

    Article  PubMed  Google Scholar 

  • Meador-Woodruff JH, Healy DJ (2000) Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31:288–294

    Article  PubMed  CAS  Google Scholar 

  • Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW (2000) Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 20:1–6

    Google Scholar 

  • Mehta MA, Swainson R, Gogilvie AD, Sahakian BJ, Robbins TW (2001) Improved short-term spatial memory but impaired reversal learning following the dopamine D2 agonist bromocriptine in human volunteers. Psychopharmacology 159:10–20

    Article  PubMed  CAS  Google Scholar 

  • Melchitzky DS, Lewis DA (2003) Pyramidal neuron local axon terminals in monkey prefrontal cortex: differential targeting of subclasses of GABA neurons. Cereb Cortex 13:452–460

    Article  PubMed  Google Scholar 

  • Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 130:1007S–1115S

    PubMed  CAS  Google Scholar 

  • Menzies L, Ooi C, Kamath S, Suckling J, McKenna P, Fletcher P, Bullmore E, Stephenson C (2007) Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 64:156–167

    Article  PubMed  CAS  Google Scholar 

  • Minzenberg MJ, Carter CS (2008) Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33:1477–1502

    Article  PubMed  CAS  Google Scholar 

  • Minzenberg MJ, Watrous AJ, Yoon JH, Ursu S, Carter CS (2008) Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI. Science 322:1700–1702

    Article  PubMed  CAS  Google Scholar 

  • Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC (2009) Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry 66:811–822

    Article  PubMed  Google Scholar 

  • Mohan M, Carpenter PK, Bennett C (2009) Donepezil for dementia in people with Down syndrome. Cochrane Database Syst Rev CD007178

    Google Scholar 

  • Morein-Zamir S, Turner DC, Sahakian BJ (2007) A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull 33:1298–1306

    Article  PubMed  Google Scholar 

  • Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS (2007) A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 94:332–341

    Article  PubMed  Google Scholar 

  • Muller U, von Cramon Y, Pollmann S (1998) D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 18:2720–2728

    PubMed  CAS  Google Scholar 

  • Myers CS, Robles O, Kakoyannis AN, Sherr JD, Avila MT, Blaxton TA, Thaker GK (2004) Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) 174:334–340

    Article  CAS  Google Scholar 

  • Newcomer JW, Krystal JH (2001) NMDA receptor regulation of memory and behavior in humans. Hippocampus 11:529–542

    Article  PubMed  CAS  Google Scholar 

  • Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118

    Article  PubMed  CAS  Google Scholar 

  • Niendam TA, Bearden CE, Rosso IM, Sanchez LE, Hadley T, Nuechterlein KH, Cannon TD (2003) A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am J Psychiatry 160:2060–2062

    Article  PubMed  Google Scholar 

  • Noren U, Bjorner A, Sonesson O, Eriksson L (2006) Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophr Res 85:302–304

    Article  PubMed  CAS  Google Scholar 

  • Olincy A, Young DA, Freedman R (1997) Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 42:1–5

    Article  PubMed  CAS  Google Scholar 

  • Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630–638

    Article  PubMed  CAS  Google Scholar 

  • Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523–533

    Article  PubMed  CAS  Google Scholar 

  • Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR (2007) A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry 68:705–710

    Article  PubMed  CAS  Google Scholar 

  • Polinsky RJ (1998) Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 20:634–647

    Article  PubMed  CAS  Google Scholar 

  • Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL (1998) Postmortem studies in schizophrenia. Schizophr Bull 24:325–341

    Article  PubMed  CAS  Google Scholar 

  • Power AE, Vazdarjanova A, McGaugh JL (2003) Muscarinic cholinergic influences in memory consolidation. Neurobiol Learn Mem 80:178–193

    Article  PubMed  CAS  Google Scholar 

  • Razay G, Wilcock GK (2008) Galantamine in Alzheimer's disease. Expert Rev Neurother 8:9–17

    Article  PubMed  CAS  Google Scholar 

  • Reingold JL, Morgan JC, Sethi KD (2007) Rivastigmine for the treatment of dementia associated with Parkinson's disease. Neuropsychiatr Dis Treat 3:775–783

    PubMed  CAS  Google Scholar 

  • Rosenthal MH, Bryant SL (2004) Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 27:38–43

    Article  PubMed  CAS  Google Scholar 

  • Sacco KA, Creeden C, Reutenauer EL, George TP (2008) Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. Schizophr Res 103:326–327

    Article  PubMed  Google Scholar 

  • Sacco KA, Creeden C, Reutenauer EL, Vessicchio JC, Weinberger AH, George TP (2009) Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res 107:332–333

    Article  PubMed  Google Scholar 

  • Sawaguchi T, Goldman-Rakic PS (1994) The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 71:515–528

    PubMed  CAS  Google Scholar 

  • Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14:1017–1023

    Article  PubMed  CAS  Google Scholar 

  • Schilstrom B, Ivanov VB, Wiker C, Svensson TH (2007) Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32:43–53

    Article  PubMed  CAS  Google Scholar 

  • Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 113:1625–1644

    Article  PubMed  CAS  Google Scholar 

  • Schubert MH, Young KA, Hicks PB (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60:530–553

    Article  PubMed  CAS  Google Scholar 

  • Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1–58

    Article  PubMed  CAS  Google Scholar 

  • Seidman LJ, Giuliano AJ, Smith CW, Stone WS, Glatt SJ, Meyer E, Faraone SV, Tsuang MT, Cornblatt B (2006) Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside adolescent high risk studies. Schizophr Bull 32:507–524

    Article  PubMed  Google Scholar 

  • Sevy S, Rosenthal MH, Alvir J, Meyer S, Visweswaraiah H, Gunduz-Bruce H, Schooler NR (2005) Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 66:839–843

    Article  PubMed  CAS  Google Scholar 

  • Sharma T, Reed C, Aasen I, Kumari V (2006) Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 85:73–83

    Article  PubMed  Google Scholar 

  • Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033–1039

    Article  PubMed  Google Scholar 

  • Siegel BV, Trestman RL, O'Faithbheartaigh S, Mitropoulou V, Amin F, Kirrane R, Silverman J, Schmeidler J, Keefe RS, Siever LJ (1996) d-Amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophr Res 20:29–32

    Article  PubMed  Google Scholar 

  • Silver H, Geraisy N (1995) Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A double-blind cross-over study. Br J Psychiatry 166:241–243

    Article  PubMed  CAS  Google Scholar 

  • Silver H, Goodman C, Isakov V, Knoll G, Modai I (2005) A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol 20:319–326

    Article  PubMed  Google Scholar 

  • Smith RC, Singh A, Infante M, Khandat A, Kloos A (2002) Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27:479–497

    Article  PubMed  CAS  Google Scholar 

  • Smith RC, Warner-Cohen J, Matute M, Butler E, Kelly E, Vaidhyanathaswamy S, Khan A (2006) Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31:637–643

    Article  PubMed  CAS  Google Scholar 

  • Snitz BE, Macdonald AW III, Carter CS (2006) Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 32:179–194

    Article  PubMed  Google Scholar 

  • Sorensen HJ, Mortensen EL, Parnas J, Mednick SA (2006) Premorbid neurocognitive functioning in schizophrenia spectrum disorder. Schizophr Bull 32:578–583

    Article  PubMed  Google Scholar 

  • Spence SA, Green RD, Wilkinson ID, Hunter MD (2005) Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 187:55–61

    Article  PubMed  Google Scholar 

  • Stover E, Marder S, Carpenter W (2007a) Progress on NIMH initiatives (memorial theme for Wayne Fenton, MD). Schizophr Bull 33:1084–1085

    Article  PubMed  Google Scholar 

  • Stover EL, Brady L, Marder SR (2007b) New paradigms for treatment development. Schizophr Bull 33:1093–1099

    Article  PubMed  Google Scholar 

  • Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA (1999) Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol Psychiatry 45:680–686

    Article  PubMed  CAS  Google Scholar 

  • Tamminga CA (2006) The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67:e11

    Article  PubMed  Google Scholar 

  • Terry AV Jr (2008) Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol 6:286–292

    Article  PubMed  CAS  Google Scholar 

  • Toda M, Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9:329–336

    Article  PubMed  Google Scholar 

  • Toulopoulou T, Rabe-Hesketh S, King H, Murray RM, Morris RG (2003) Episodic memory in schizophrenic patients and their relatives. Schizophr Res 63:261–271

    Article  PubMed  CAS  Google Scholar 

  • Tsuno N (2009) Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother 9:591–598

    Article  PubMed  CAS  Google Scholar 

  • Tugal O, Yazici KM, Anil Yagcioglu AE, Gogus A (2004) A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 7:117–123

    Article  PubMed  CAS  Google Scholar 

  • Turner D (2006) A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother 6:455–468

    Article  PubMed  CAS  Google Scholar 

  • Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003) Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165:260–269

    CAS  Google Scholar 

  • Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004a) Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 55:1031–1040

    Article  PubMed  CAS  Google Scholar 

  • Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004b) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29:1363–1373

    Article  PubMed  CAS  Google Scholar 

  • Tuulio-Henriksson A, Arajarvi R, Partonen T, Haukka J, Varilo T, Schreck M, Cannon T, Lönnqvist J (2003) Familial loading associates with impairment in visual span among healthy siblings of schizophrenia patients. Biol Psychiatry 54:623–628

    Article  PubMed  Google Scholar 

  • Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA (2000) Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 57:237–245

    Article  PubMed  CAS  Google Scholar 

  • Volk D, Austin M, Pierri J, Sampson A, Lewis D (2001) GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 158:256–265

    Article  PubMed  CAS  Google Scholar 

  • Waldo M, Myles-Worsley M, Madison A, Byerley W, Freedman R (1995) Sensory gating deficits in parents of schizophrenics. Am J Med Genet 60:506–511

    Article  PubMed  CAS  Google Scholar 

  • Walker E, Diforio D (1997) Schizophrenia: a neural diathesis-stress model. Psychol Rev 104:667–685

    Article  PubMed  CAS  Google Scholar 

  • Walker DP, Wishka DG, Piotrowski DW, Jia S, Reitz SC, Yates KM, Myers JK, Vetman TN, Margolis BJ, Jacobsen EJ, Acker BA, Groppi VE, Wolfe ML, Thornburgh BA, Tinholt PM, Cortes-Burgos LA, Walters RR, Hester MR, Seest EP, Dolak LA, Han F, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Hajos M, Hoffmann WE, Li KS, Higdon NR, Wall TM, Hurst RS, Wong EH, Rogers BN (2006) Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem 14:8219–8248

    Article  PubMed  CAS  Google Scholar 

  • Wang D, Noda Y, Zhou Y, Mouri A, Mizoguchi H, Nitta A, Chen W, Nabeshima T (2007) The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25–35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32:1261–1271

    Article  PubMed  CAS  Google Scholar 

  • Williams GV, Goldman-Rakic PS (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376(17):572–575

    Article  PubMed  CAS  Google Scholar 

  • Williams LM, Whitford TJ, Flynn G, Wong W, Liddell BJ, Silverstein S, Galletly C, Harris AW, Gordon E (2007) General and social cognition in first episode schizophrenia: identification of separable factors and prediction of functional outcome using the IntegNeuro test battery. Schizophr Res 99:182–191

    Article  PubMed  Google Scholar 

  • Wonodi I, Cassady SL, Adami H, Avila M, Thaker GK (2006) Effects of repeated amphetamine administration on antisaccade in schizophrenia spectrum personality. Psychiatry Res 141:237–245

    Article  PubMed  CAS  Google Scholar 

  • Young DA, Waldo M, Rutledge JH III, Freedman R (1996) Heritability of inhibitory gating of the P50 auditory-evoked potential in monozygotic and dizygotic twins. Neuropsychobiology 33:113–117

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Yamada M, Gomeza J, Basile AS, Wess J (2002) Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1–M5 muscarinic receptor knock-out mice. J Neurosci 22:6347–6352

    PubMed  CAS  Google Scholar 

  • Zhang J, Xiong B, Zhen X, Zhang A (2009) Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev 29:272–294

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr. Barch has received grants from the NIMH, NIA, NARSAD, Novartis, and the McDonnel Center for Systems Neuroscience.

Author information

Authors and Affiliations

  1. Washington University in St. Louis, One Brookings Drive, 1125, St. Louis, MO, 63130, USA

    Deanna M. Barch

Authors
  1. Deanna M. Barch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deanna M. Barch .

Editor information

Editors and Affiliations

  1. , Dept. of Psychiatry - MC 0804, University of San Diego, Gilman Drive 9500, La Jolla, 92093, USA

    Neal R. Swerdlow

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer

About this chapter

Cite this chapter

Barch, D.M. (2010). Pharmacological Strategies for Enhancing Cognition in Schizophrenia. In: Swerdlow, N. (eds) Behavioral Neurobiology of Schizophrenia and Its Treatment. Current Topics in Behavioral Neurosciences, vol 4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2010_39

Download citation

Publish with us

Policies and ethics

Search

Navigation